Psyence Group Announces Pivot from Biotech to Gold Exploration
Published on 03/21/2026 at 01:57 | Redaktion boerse-global.de
Psyence Group is poised for a fundamental transformation of its business model. The company's planned merger with GoldCoast Resource Corp will mark a complete departure from its previous focus, shifting its core operations from biotechnology to mineral resource exploration.
Shareholder and Regulatory Approval Pending
The execution of this strategic reversal remains contingent upon receiving the necessary approvals from shareholders and the relevant regulatory bodies. Once these consents are secured, the company will terminate its existing research initiatives and establish itself as a pure-play exploration entity within Ghana's gold sector.
A Transaction Enabled by Financing
A crucial financial milestone has been achieved to facilitate the merger. GoldCoast Resource Corp has successfully closed the initial portion of a private placement, raising approximately $5.8 million. This involved the issuance of more than 6.8 million shares at a price of $0.85 each. This capital injection was a key prerequisite for the proposed combination of the two firms. Additional funding rounds at the same share price are expected in the coming weeks to finance exploration programs and provide working capital.
Should investors sell immediately? Or is it worth buying Psyence?
From Life Sciences to Natural Resources
Upon completion of the transaction, the company's operational focus will undergo a radical shift. Psyence's historical specialization in psilocybin product research will be entirely replaced by a new primary objective: gold exploration off the coast of Ghana. This move represents a total strategic realignment, transitioning the business from the life science sector into the natural resources industry.
Ad
Psyence Stock: New Analysis - 21 March
Fresh Psyence information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
